Travere Therapeutics (TVTX) Net Equity Issued and Repurchased (2013 - 2022)

Travere Therapeutics (TVTX) has 6 years of Net Equity Issued and Repurchased data on file, last reported at -$20.1 million in Q4 2022.

• Quarterly Net Equity Issued and Repurchased fell 110.9% year-over-year to -$20.1 million in Q4 2022, while the trailing twelve-month figure through Sep 2022 was $204.5 million (up 354.63% YoY) and the FY2024 annual result came in at $134.7 million, down 29.53% from the prior year.
• Net Equity Issued and Repurchased fell to -$20.1 million in Q4 2022, from $20.1 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $184.4 million in Q4 2021 to a low of -$85.2 million in Q4 2020.
• A 3-year average of $26.6 million and a median of $2.4 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased soared 316.45% — and 2022, when it sank 110.9%.
• Tracing TVTX's Net Equity Issued and Repurchased over 3 years: stood at -$85.2 million in 2020, then soared by 316.45% to $184.4 million in 2021, then tumbled by 110.9% to -$20.1 million in 2022.
• The last three Net Equity Issued and Repurchased figures came in at -$20.1 million (Q4 2022), $20.1 million (Q1 2022), and $184.4 million (Q4 2021), per Business Quant data.